Adobe Stock Photos

Teva Pharmaceutical Stock (TEVA) Trading Higher Today on FDA Approval of Its Seizure Drug Sabril for Adults and Pediatric Epilepsy Patients

FDA News Release

FDA approves first generic version of Sabril to help treat seizures in adults and pediatric patients with epilepsy

For Immediate Release
January 16, 2019

Release
The U.S. Food and Drug Administration approved the first generic version of Sabril (vigabatrin) 500 mg tablets for treating complex partial seizures, also called focal seizures, as an adjunctive therapy (given with another primary treatment) in patients 10 years and older who have responded inadequately to several alternative (refractory) treatments.

“Prioritizing the approval of generic drugs to compete with medicines that face little or no competition is a key part of our efforts to support access and reduce drug costs to patients. The availability of high-quality generic alternatives of critically important medicines, once the period of patent protection or exclusivity has ended on the brand drug, helps advance access and saves consumers billions of dollars each year,” said FDA Commissioner Scott Gottlieb, M.D. “We know there has been past interest in developing a generic alternative to this product. Earlier this year, we also highlighted this drug, along with many others, on a list of off-patent, off-exclusivity branded drugs without approved generics, to clarify that there were no patents or exclusivities that should impede its approval. Today’s action demonstrates that there is an open pathway to approving products like this one. We’re especially focused on new policies aimed at making the generic review process more predictable, efficient and lower cost so we can entice more generic firms to enter this space, and help facilitate more generic drug launches after generic approvals. We know it’s not enough just to approve a record number of generic medicines. We also want to see firms launch these products so that patients can benefit from their availability, and we intend to take steps to advance these goals.”

Complex partial seizures, a common type of seizures, start in a specific area of the brain and can affect consciousness. Typically, complex partial seizures last between 30 and 90 seconds, and are often followed by a period of disorientation, confusion and/or fatigue.

The FDA requires appropriate data and information to demonstrate that generic drugs meet the agency’s rigorous approval standards to ensure quality drug products that are as safe and effective as their brand name counterparts. As with brand-name drugs, the FDA also inspects manufacturing and packaging facilities for generic drugs to ensure that they are capable of consistently producing quality products.

Labeling for vigabatrin tablets includes a boxed warning for permanent vision loss. Teva’s generic vigabatrin tablets is part of a single shared-system Risk Evaluation and Mitigation Strategy (REMS) program with other drug products containing vigabatrin to ensure safe use of the product. Brand and generic drug makers are required to develop a single shared-system REMS program (unless FDA waives the single shared system requirement) when a generic drug seeks approval and the brand drug has a REMS associated with it.

The most common side effects associated with vigabatrin tablets include dizziness, fatigue, sleepiness (somnolence), involuntary eye movement (nystagmus), tremor, blurred vision, memory impairment, weight gain, joint pain (arthralgia), upper respiratory tract infection, aggression, double vision (diplopia), abnormal coordination and a confused state. Serious side effects associated with vigabatrin tablets include permanent vision loss and risk of suicidal thoughts or actions.

Last year, the FDA began to publish a list of inquiries from generic drug developers seeking the FDA’s assistance in obtaining samples from brand companies, which included Sabril, noting these brand companies were potentially blocking access to the samples of their brand products when the brand products are subject to limited distribution programs, including REMS. The FDA has continued to emphasize that even in the case of limited distribution programs, there should be a path forward for generic drug development. Additionally, the FDA’s list of off-patent, off-exclusivity branded drugs without approved generics is an effort the FDA began in 2017 and will continue to refine and update periodically to ensure continued transparency around drug categories where increased competition has the potential to provide significant benefit to patients.

Today’s approval of generic vigabatrin tablets was granted to Teva Pharmaceuticals USA.

For more information:

FDA: Generic Drugs
FDA: First Generic Drug Approvals
FDA: Drug Competition Action Plan
FDA Tackles Drug Competition to Improve Patient Access
FDA: List of Off-Patent, Off-Exclusivity Drugs without an Approved Generic
###

Related Video:

Source

FDA approves first generic version of Sabril to help treat seizures in adults and pediatric patients with epilepsy

The U.S. Food and Drug Administration approved the first generic version of Sabril (vigabatrin) 500 mg tablets for treating complex partial seizures, also called focal seizures, as an adjunctive therapy (given with another primary treatment) in patients 10 years and older who have responded inadequately to several alternative (refractory) treatments.

Check Also

The Conference Board Economics Watch: Europe Brief – January 2019

Despite the moderate outlook, the unemployment rate in the Euro area has remained stable at 8.1 percent, since the summer of 2018. With unemployment reaching a decade low, companies feel the pain of talent shortages, especially in an aging labor market.

Brexit Uncertainty to Continue for at Least Another Two Months

A Statement from The Conference Board Press Release Provided By The Conference Board Jan 16, …

photos by pexels.com

Brexit Analysis: How Immigration, the Irish Border and Changes to Tariffs will Affect Retail Markets with Sector Analysis of the Individual Retail

As the UK approaches the 29th March 2019, companies are yet to fully comprehend the impact Brexit will have on retail. As political negotiations and parliamentary votes are yet to settle the final rules and implications of the UK's departure, unknown territory must be navigated in planning for the Brexit transition process.

photos by pexels.com

Canopy Growth Receives New York State Hemp Licence and Will Establish U.S.-Based Commercial Operations

"Canopy Growth's $100-$150 million investment in the Southern Tier is a true win-win - for Canopy Growth, who will be positioned at the forefront of Upstate New York's industrial hemp revolution, and for the Southern Tier's economy and farmers, which will receive a major shot in the arm in new good-paying jobs. I fought so hard to strip the burdensome federal regulations from industrial hemp in our Industrial Hemp Farming Act of 2018, which was recently included in the Farm Bill, because I knew how much it could mean to the Southern Tier, and this investment proves it. I'm so pleased that Canopy Growth is joining my efforts to make the Southern Tier the Silicon Valley of industrial hemp production and research and will keep pushing to see industrial hemp become a true cash crop in the region," said Senator Schumer.

rawpixel.com photo

The Food and Drug Administration (FDA) Just Approved a Diagnostic Test to Assist Healthcare Providers in Measuring Nutrients in Breast Milk

The FDA reviewed data submitted by the sponsor of 112 samples of human milk to analyze the performance of the device. For the study, the sponsor tested the same 112 samples in the machine and compared them to the expected true values obtained by independent methods; both systems provided similar results for each test. The data showed that the Miris Human Milk Analyzer test was effective at determining levels of protein, fat and carbohydrate in the milk. There may be conditions that limit the information available from the Miris Human Milk Analyzer. For example, certain medications that a nursing mother may be taking could interfere with the test’s ability to accurately measure nutrient levels in breast milk.

Isaac Lieberman Discusses How His Aston Capital Management Hedge Fund Acts as a Supplier of Non-Bank Liquidity Provisioning

We look at ourselves as a quantitative hedge fund and liquidity provisioning being a business line, and that we have investor capital in terms of AUM and one of our businesses is we provide liquidity in global foreign exchange markets five and a half days a week 24 hours a day in 31 currency pairs.

Photo by rawpixel on Unsplash

When Interest Rates Rise: Winners and Losers

The green back has appreciated over 20% against other currencies since July 2014 in anticipation of a rate hike. A strong dollar is a positive for consumers buying goods or traveling overseas, but the flipside is that a strong dollar ends up hurting American exporters.

%d bloggers like this: